Symbiotec Pharmalab posts nearly 53% YoY fall in Q1 PAT
A quarterly results development with market-wide reach.
22 Sept 2026 · Business Standard Mkts
Symbiotec Pharmalab has reported 52.8% fall in consolidated net profit to Rs 14.1 crore despite a 7% rise in revenue from operations to Rs 218.2 crore in Q1 FY27 as compared with Q1 FY26.
Key facts
- Period
- Q1 FY27 and Q1 FY26
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- The immediate tone of coverage reads negative.
Related coverage
Invesco and Motilal Oswal lead AUM growth in Q2 FY27, shows data
TCS Q2 earnings: Five things to watch as Tata boardroom fight adds to scrutiny
Satin Creditcare Network shares gain 4% after Q2 business update; AUM rises 31% YoY
Q2 Results Preview: Nifty 50 Earnings May Jump 27%; Financials, Metals, Telecom To Lead, Says Motilal Oswal
Penny stock under ₹10 hits 5% upper circuit after this fundraising update | Do you own?